000 04211nam a22005535i 4500
001 978-3-031-71180-0
003 DE-He213
005 20251030114631.0
007 cr nn 008mamaa
008 241221s2024 sz | s |||| 0|eng d
020 _a9783031711800
_9978-3-031-71180-0
024 7 _a10.1007/978-3-031-71180-0
_2doi
050 4 _aRC633-647
072 7 _aMJF
_2bicssc
072 7 _aMED038000
_2bisacsh
072 7 _aMJF
_2thema
245 1 0 _aAcute Lymphoblastic Leukemia in Children and Adolescents
_h[electronic resource] /
_cedited by Gabriele Escherich, Valentino Conter.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer Nature Switzerland :
_bImprint: Springer,
_c2024.
300 _aIX, 397 p. 35 illus., 34 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aPediatric Oncology,
_x2191-0812
505 0 _aPart I: Epidemiology and Predisposition of ALL. Genetic predisposition for leukemia -- Association of leukemia with genetic diseases. Part II: Biology and Diagnostics of ALL. Genetic aberrations and profiles in Bcp ALL -- Genetic aberrations and profiles in T ALL -- Features of ALL in children, adolescents, and young adults -- Immunological Diagnosis -- MRD response: FCM, Ig/Tcr PCR, NGS. Part III: Stratification and treatment considerations in ALL. Stratification and treatment of Bcp ALL and T-ALL -- Stratification and treatment of Adolescents/AYA -- CNS therapy -- Stratification and treatment of Down Syndrome -- Stratification and treatment of Infants -- Stratification and treatment of BCR/ABL and ABL class fusion. Part IV: Immunotherapy in ALL. Immunotherapy with monoclonal antibodies -- Immunotherapy with CAR-T. Part V: Strategies for patients with Lymphoblastic Lymphoma/mature B-ALL. Stratification and treatment of lymphoblastic lymphomas -- Stratification and treatment of mature B ALLs. Part VI: Strategies for patients with refractory or relapsed ALL. Relapses: classification and treatment -- HSCT in 1rst CR and after subsequent CRs: indications, conditioning regimens. Part VII: Toxicity and Late effects following ALL treatment. Genetic disposition for toxicity Late toxicity including SMN -- late effects after HSCT. Part VIII: Perspectives and Future directions -- Global disparities in ALL treatment and outcome -- New agents.
520 _aThis book is a comprehensive and up-to-date compendium on diagnosis, treatment and late effects of Acute Lymphoblastic Leukemia in children, adolescents and young adults. After introductory chapters on the epidemiology and biology of ALL, treatment considerations are extensively reviewed, also with emphasis on special patient groups, such as Infants, Adolescents and patients with Down Syndrome. Immunotherapy in Acute Lymphoblastic Leukemia is reviewed as well as strategies for patients with Lymphoblastic Lymphoma and for patients with refractory or relapsed ALL. The authors are internationally recognized experts and offer up-to-date insights on etiology, biology, and treatment. This book will prove indispensable for those treating or researching into this disease.
650 0 _aHematology.
_976927
650 0 _aPediatrics.
_964087
650 0 _aOncology.
_970760
650 1 4 _aHematology.
_976927
650 2 4 _aPediatrics.
_964087
650 2 4 _aOncology.
_970760
700 1 _aEscherich, Gabriele.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_989309
700 1 _aConter, Valentino.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_989310
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031711794
776 0 8 _iPrinted edition:
_z9783031711817
776 0 8 _iPrinted edition:
_z9783031711824
830 0 _aPediatric Oncology,
_x2191-0812
_977125
856 4 0 _uhttps://doi.org/10.1007/978-3-031-71180-0
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c65914
_d65914